ELCC 2022 | TKIs in patients with oncogene driven NSCLC and brain metastasis

Jordi Remon, MD, PhD, HM CIOCC – Centro Integral Oncológico Clara Campal, Barcelona, Spain, discusses the management of patients with non-small cell lung cancer (NSCLC) with brain metastases at baseline. Patients with common oncogenic drivers, such as ALK rearrangement and ROS1, can be initially treated with a tyrosine kinase inhibitor (TKI), possibly delaying the requirement for radiotherapy. Dr Remon explains that the primary and metastatic tumor is likely to be homogenous in in regards to oncogenic drivers, and can thus be treated with the same TKI. The question is whether there are a subgroup of patients that could benefit from the combined treatment of TKIs and radiotherapy. This interview took place during the virtual European Lung Cancer Congress 2022.